NervGen Pharma Corp. Achieves Breakthrough in Spinal Cord Injury Treatment

In a significant development for the biotech sector, NervGen Pharma Corp., a Vancouver-based company specializing in neurodegenerative and nerve damage treatments, has reported promising results from its Phase 1b/2a clinical trial of NVG-291, a drug aimed at treating spinal cord injuries (SCI). The trial’s chronic cohort has met its primary endpoint, marking a pivotal moment in SCI treatment research.

The study demonstrated increased electrical connectivity between the brain and hand muscles in individuals with cervical level spinal cord injuries. This achievement is particularly noteworthy as it represents the first instance of a pharmaceutical candidate showing improved motor recovery based on increased motor evoked potential amplitude. Such a breakthrough is crucial in a field where no approved pharmaceuticals currently exist to enable sustained functional recovery for SCI patients.

Additionally, the trial exhibited a positive trend in the secondary endpoint, which evaluated changes in the “GRASSP” score. This score is specifically designed to assess hand function in individuals with cervical injuries, further underscoring the potential of NVG-291 to enhance motor function in SCI patients.

The implications of these findings are profound. NervGen Pharma’s NVG-291 could potentially revolutionize the treatment landscape for spinal cord injuries, offering hope for improved quality of life for those affected. The company plans to review these results and its development strategy with the U.S. Food and Drug Administration (FDA), signaling the next steps towards bringing this promising treatment to market.

These topline results will be presented at the American Spinal Injury Association (ASIA) Annual Scientific Meeting on June 3, 2025. An investor and analyst call to discuss the data is also scheduled for the same day, providing stakeholders with an opportunity to delve deeper into the study’s outcomes and future implications.

NervGen Pharma Corp., listed on the TSX Venture Exchange, has seen its stock close at CAD 5.15 on May 29, 2025, with a market capitalization of CAD 388,290,000. Despite a negative price-to-earnings ratio of -14.78, the company’s recent breakthrough could positively influence investor sentiment and market performance.

As the biotech community and SCI patients eagerly await further developments, NervGen Pharma’s progress with NVG-291 stands as a testament to the potential of innovative pharmaceutical research in addressing some of the most challenging medical conditions.